Endothelin antagonism as an active principle for glaucoma therapy

Area of Science:

• Ophthalmology
• Pharmacology
• Neuroscience

Background:

• Open-angle glaucoma is a leading cause of optic nerve neuropathy, characterized by retinal ganglion cell loss and visual field deficits.
• Elevated intraocular pressure is a primary risk factor, but reduced ocular blood flow also contributes significantly to disease pathogenesis.
• Endothelin, a potent vasoconstrictor, influences intraocular pressure regulation and ocular hemodynamics.

Purpose of the Study:

• To investigate the role of endothelin in the pathogenesis of open-angle glaucoma.
• To explore the potential of endothelin antagonism as a therapeutic strategy for glaucoma.

Main Methods:

• The study reviews the known effects of endothelin on trabecular outflow and ocular blood flow.
• It examines how endothelin signaling impacts trabecular meshwork contractility and retinal/optic nerve head vasculature.
• The neuroprotective effects of endothelin inhibition are discussed in the context of retinal ganglion cell degeneration.

Main Results:

• Endothelin modulates intraocular pressure by affecting aqueous humor outflow through the trabecular meshwork.
• Endothelin causes vasoconstriction, decreasing ocular blood flow and potentially leading to retinal and optic nerve damage.
• Inhibition of endothelin signaling was shown to lower intraocular pressure.

Conclusions:

• Endothelin signaling contributes to open-angle glaucoma through effects on intraocular pressure and ocular blood flow.
• Endothelin antagonism demonstrates neuroprotective effects and lowers intraocular pressure.
• Targeting endothelin pathways presents a promising avenue for novel pharmacological glaucoma treatments.